Association between mitochondrial haplogroups and ranibizumab response in neovascular age-related macular degeneration
Ascaso, F. (Universidad de Zaragoza) ; Esteban, O. ; Montoya, J. (Universidad de Zaragoza) ; Montes, P. ; Mateo, J. ; Lara, J. ; Ruiz-Pesini, E. (Universidad de Zaragoza)
Resumen: Purpose : The association between mitochondrial DNA (mtDNA) haplogroup and the risk of neovascular age-related macular degeneration (nAMD) has been reported. This prospective, observational clinical study analyzes the anatomical and functional outcomes after one year of intravitreal ranibizumab therapy in nAMD patients according to the mt-DNA haplogroup.
Methods : Ninety-eight eyes corresponding to 91 patients with nAMD were treated with three consecutive monthly intravitreal ranibizumab 0.5 mg followed by a flexible pro re nata (PRN). Retreatment criteria were: loss =5 ETDRS letters; increased central foveal thickness (CFT) >100 µm; intra or subretinal fluid on OCT; new or persistent macular haemorrhages. Exclusion criteria were previous treatment with photodynamic therapy or anti-VEGF drug; vitrectomy or any other retinal disease; corneal or lens opacities. Patients were classified into four groups according to their mtDNA haplogroup determined by PCR (Hg H- m.7028C>T; Hg HV- m.14766T>C; Hg JT- m.421 6T>C and Hg U- m.12308A>G). Chi-square, Kolmogorov-Smirnov, ANOVA, Mann-Whitney, Kruskal-Wallis, analysis of variance, Wilcoxon, and Friedman tests were used. SPSS 21.0 program. A p value < 0.05 was statistically significant.
Results : Gender, age, risk factors (smoking, diabetes, arterial hypertension and dyslipidemia) and neovascular lesion type were equally distributed among four groups. There were no significant differences between groups in baseline or after loading fase in best corrected visual acuity (BCVA) or CFT. At 4 months, BCVA was significantly higher than baseline in haplogroups HV (p = 0.02), JT (p = 0.002) and U (p = 0.002). CFT was significantly lower in all haplogroups (HV, p<0.001;JT, p=0.028;U, p=0.043;Others, p=0.007). Eighteen patients were excluded at 12 months because of exclusion criteria, however baseline variables were equally distributed among four groups. At 12 months, BCVA in HV and U did not show significant worsening; however, JT showed lower BCVA values than baseline. CFT values in JT were higher than baseline (p = 1.00), whereas HV and U were significantly lower than baseline (HV, p < 0.001; U, p = 0.007). CFT values were significantly different between JT and U (p = 0.010).
Conclusions : mtDNA haplogroups showed different response to ranibizumab at 12 month. It could be a potencial biomarker to predict the response to this therapy in nAMD patients.
Idioma: Inglés
Año: 2019
Publicado en: Investigative ophthalmology & visual science 60, 9 (2019), [3 pp]
ISSN: 0146-0404
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 3.47 (2019)
Categ. JCR: OPHTHALMOLOGY rank: 10 / 60 = 0.167 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.789 - Ophthalmology (Q1) - Sensory Systems (Q1) - Cellular and Molecular Neuroscience (Q2)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2021-12-16-13:05:24)
Visitas y descargas
Methods : Ninety-eight eyes corresponding to 91 patients with nAMD were treated with three consecutive monthly intravitreal ranibizumab 0.5 mg followed by a flexible pro re nata (PRN). Retreatment criteria were: loss =5 ETDRS letters; increased central foveal thickness (CFT) >100 µm; intra or subretinal fluid on OCT; new or persistent macular haemorrhages. Exclusion criteria were previous treatment with photodynamic therapy or anti-VEGF drug; vitrectomy or any other retinal disease; corneal or lens opacities. Patients were classified into four groups according to their mtDNA haplogroup determined by PCR (Hg H- m.7028C>T; Hg HV- m.14766T>C; Hg JT- m.421 6T>C and Hg U- m.12308A>G). Chi-square, Kolmogorov-Smirnov, ANOVA, Mann-Whitney, Kruskal-Wallis, analysis of variance, Wilcoxon, and Friedman tests were used. SPSS 21.0 program. A p value < 0.05 was statistically significant.
Results : Gender, age, risk factors (smoking, diabetes, arterial hypertension and dyslipidemia) and neovascular lesion type were equally distributed among four groups. There were no significant differences between groups in baseline or after loading fase in best corrected visual acuity (BCVA) or CFT. At 4 months, BCVA was significantly higher than baseline in haplogroups HV (p = 0.02), JT (p = 0.002) and U (p = 0.002). CFT was significantly lower in all haplogroups (HV, p<0.001;JT, p=0.028;U, p=0.043;Others, p=0.007). Eighteen patients were excluded at 12 months because of exclusion criteria, however baseline variables were equally distributed among four groups. At 12 months, BCVA in HV and U did not show significant worsening; however, JT showed lower BCVA values than baseline. CFT values in JT were higher than baseline (p = 1.00), whereas HV and U were significantly lower than baseline (HV, p < 0.001; U, p = 0.007). CFT values were significantly different between JT and U (p = 0.010).
Conclusions : mtDNA haplogroups showed different response to ranibizumab at 12 month. It could be a potencial biomarker to predict the response to this therapy in nAMD patients.
Idioma: Inglés
Año: 2019
Publicado en: Investigative ophthalmology & visual science 60, 9 (2019), [3 pp]
ISSN: 0146-0404
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 3.47 (2019)
Categ. JCR: OPHTHALMOLOGY rank: 10 / 60 = 0.167 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.789 - Ophthalmology (Q1) - Sensory Systems (Q1) - Cellular and Molecular Neuroscience (Q2)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2021-12-16-13:05:24)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Bioquímica y Biología Molecular
Articles > Artículos por área > Oftalmología
Record created 2021-01-28, last modified 2021-12-16